UA104002C2 - МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА КАК ИНГИБИТОРЫ TAFIa - Google Patents
МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА КАК ИНГИБИТОРЫ TAFIaInfo
- Publication number
- UA104002C2 UA104002C2 UAA201100191A UAA201100191A UA104002C2 UA 104002 C2 UA104002 C2 UA 104002C2 UA A201100191 A UAA201100191 A UA A201100191A UA A201100191 A UAA201100191 A UA A201100191A UA 104002 C2 UA104002 C2 UA 104002C2
- Authority
- UA
- Ukraine
- Prior art keywords
- heading
- inhibitors
- tafia
- normal
- sulfamide derivatives
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1
- 239000004202 carbamide Substances 0.000 title 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102100035023 Carboxypeptidase B2 Human genes 0.000 abstract 1
- 108090000201 Carboxypeptidase B2 Proteins 0.000 abstract 1
- 208000005189 Embolism Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000009863 secondary prevention Effects 0.000 abstract 1
- 201000005665 thrombophilia Diseases 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/01—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08290520 | 2008-06-06 | ||
| PCT/EP2009/003650 WO2009146802A1 (de) | 2008-06-06 | 2009-05-22 | Makrocyclische harnstoff- und sulfamidderivate als inhibitoren von tafia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA104002C2 true UA104002C2 (ru) | 2013-12-25 |
Family
ID=39800716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201100191A UA104002C2 (ru) | 2008-06-06 | 2009-05-22 | МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА КАК ИНГИБИТОРЫ TAFIa |
Country Status (34)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2494390T3 (es) | 2008-06-06 | 2014-09-15 | Sanofi | Derivados macrocíclicos de urea y de sulfamida como inhibidores de TAFIa |
| AU2009263076B2 (en) | 2008-06-23 | 2012-07-26 | Astrazeneca Ab | New heterocyclic carboxamides for use as thrombin inhibitors |
| US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| ME02630B (me) * | 2012-03-06 | 2017-06-20 | Pfizer | Makrociklički derivati, namijenjeni liječenju proliferativnih bolesti |
| EP3027611B1 (en) * | 2013-06-10 | 2017-07-26 | Sanofi | Macrocyclic urea derivatives as inhibitors of tafi a, their preparation and their use as pharmaceuticals |
| UY35809A (es) * | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
| CN103755852B (zh) * | 2013-12-18 | 2015-12-09 | 湖北大学 | 线型聚苯乙烯支载(4s)-(4’-氧苄基)-2-正丁基环磺酰胺及其制备方法和用途 |
| CN106631832A (zh) * | 2016-10-08 | 2017-05-10 | 帕潘纳(北京)科技有限公司 | 一种氨基醚类化合物的制备方法 |
| US10411291B2 (en) * | 2017-03-22 | 2019-09-10 | Nanotek Instruments, Inc. | Multivalent metal ion battery having a cathode layer of protected graphitic carbon and manufacturing method |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU667995B2 (en) | 1993-02-15 | 1996-04-18 | Bayer Aktiengesellschaft | New pseudopeptides having an antiviral action |
| TW394760B (en) | 1993-09-07 | 2000-06-21 | Hoffmann La Roche | Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same |
| US5888971A (en) * | 1996-02-20 | 1999-03-30 | Ortho Pharmaceutical Corporation, Inc. | Macrocyclic peptides useful in the treatment of thrombin related disorders |
| CA2298601A1 (en) | 1997-08-28 | 1999-03-11 | Pharmacia & Upjohn Company | Inhibitors of protein tyrosine phosphatase |
| US6124278A (en) * | 1998-04-03 | 2000-09-26 | The Regents Of The University Of California | Acylbenzoxazines for enhancing synaptic response |
| US6482921B1 (en) | 1999-01-28 | 2002-11-19 | Essential Therapeutics, Inc. | Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use |
| DE60042585D1 (de) * | 2000-02-29 | 2009-09-03 | Univ Firenze | 3-Aza-6,8-dioxabicycloÄ3.2.1Üoctane und Analoga sowie diese enthaltende kombinatorische Bibliotheken |
| DE102004020186A1 (de) * | 2004-04-22 | 2005-11-17 | Aventis Pharma Deutschland Gmbh | Heterocyclylessigsäuren als Inhibitoren von TAFla |
| AU2007327959B2 (en) | 2006-12-06 | 2013-08-01 | Sanofi-Aventis | Urea and sulfamide derivatives as tafia inhibitors |
| ES2494390T3 (es) | 2008-06-06 | 2014-09-15 | Sanofi | Derivados macrocíclicos de urea y de sulfamida como inhibidores de TAFIa |
-
2009
- 2009-05-22 ES ES09757185.5T patent/ES2494390T3/es active Active
- 2009-05-22 PL PL09757185T patent/PL2300462T3/pl unknown
- 2009-05-22 WO PCT/EP2009/003650 patent/WO2009146802A1/de not_active Ceased
- 2009-05-22 NZ NZ589671A patent/NZ589671A/en not_active IP Right Cessation
- 2009-05-22 KR KR1020107027133A patent/KR101673886B1/ko not_active Expired - Fee Related
- 2009-05-22 SI SI200931001T patent/SI2300462T1/sl unknown
- 2009-05-22 US US12/996,460 patent/US8580777B2/en not_active Expired - Fee Related
- 2009-05-22 BR BRPI0913349A patent/BRPI0913349A2/pt not_active Application Discontinuation
- 2009-05-22 DK DK09757185T patent/DK2300462T3/da active
- 2009-05-22 RU RU2010154089/04A patent/RU2502736C2/ru not_active IP Right Cessation
- 2009-05-22 HR HRP20140787AT patent/HRP20140787T1/hr unknown
- 2009-05-22 PT PT09757185T patent/PT2300462E/pt unknown
- 2009-05-22 CN CN2009801210767A patent/CN102056922B/zh not_active Expired - Fee Related
- 2009-05-22 EP EP09757185.5A patent/EP2300462B1/de active Active
- 2009-05-22 UA UAA201100191A patent/UA104002C2/ru unknown
- 2009-05-22 MX MX2010012793A patent/MX2010012793A/es active IP Right Grant
- 2009-05-22 JP JP2011512000A patent/JP5531011B2/ja not_active Expired - Fee Related
- 2009-05-22 AU AU2009254257A patent/AU2009254257B2/en not_active Ceased
- 2009-05-22 CA CA 2726554 patent/CA2726554C/en not_active Expired - Fee Related
- 2009-06-04 TW TW98118477A patent/TWI455928B/zh not_active IP Right Cessation
- 2009-06-04 UY UY31868A patent/UY31868A/es not_active Application Discontinuation
- 2009-06-04 AR ARP090102005 patent/AR072007A1/es unknown
- 2009-06-04 CL CL2009001358A patent/CL2009001358A1/es unknown
-
2010
- 2010-10-28 ZA ZA2010/07719A patent/ZA201007719B/en unknown
- 2010-11-22 NI NI201000203A patent/NI201000203A/es unknown
- 2010-11-23 CR CR11807A patent/CR11807A/es not_active Application Discontinuation
- 2010-11-23 DO DO2010000363A patent/DOP2010000363A/es unknown
- 2010-11-30 MA MA33377A patent/MA32322B1/fr unknown
- 2010-12-01 CO CO10151420A patent/CO6321271A2/es active IP Right Grant
- 2010-12-02 EC ECSP10010655 patent/ECSP10010655A/es unknown
- 2010-12-02 SV SV2010003747A patent/SV2010003747A/es unknown
- 2010-12-03 HN HN2010002558A patent/HN2010002558A/es unknown
- 2010-12-05 IL IL209772A patent/IL209772A/en not_active IP Right Cessation
-
2013
- 2013-10-08 US US14/048,339 patent/US8722655B2/en not_active Expired - Fee Related
-
2014
- 2014-03-26 US US14/226,132 patent/US9126955B2/en not_active Expired - Fee Related
- 2014-08-08 CY CY20141100631T patent/CY1115604T1/el unknown
-
2015
- 2015-07-28 US US14/811,364 patent/US9309207B2/en not_active Expired - Fee Related
-
2016
- 2016-03-01 US US15/057,920 patent/US9688645B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA104002C2 (ru) | МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА КАК ИНГИБИТОРЫ TAFIa | |
| EP2595482A4 (en) | ALDOSTERONSYNTHASEHEMMER | |
| SG179034A1 (en) | 2 -aminodihydro [1, 3] thiazines as bace 2 inhibitors for the treatment of diabetes | |
| MY140903A (en) | Imidazole derivatives used as tafia inhibitors | |
| MX2010009207A (es) | Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa. | |
| GEP20146169B (en) | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors | |
| MX2009010960A (es) | Compuestos heterociclicos y sus metodos de uso. | |
| MY151246A (en) | Benzofuranyl derivatives | |
| WO2008033562A3 (en) | Kinase inhibitor compounds | |
| MX2011011854A (es) | Dihidropirimidinonas para uso como inhibidores de la bace2. | |
| WO2008022286A3 (en) | Small molecule inhibitors of kynurenine-3-monooxygenase | |
| MY165728A (en) | Selective glycosidase inhibitors and uses thereof | |
| NO20083923L (no) | Pyrazolkinoloner er potente parp-inhibitorer | |
| HK1210174A1 (en) | Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases | |
| MX340756B (es) | Compuestos de quinazolina como inhibidores de serina/treonina quinasa. | |
| AU2011326186A8 (en) | Selective glycosidase inhibitors and uses thereof | |
| GB2466912A (en) | Compositions and methods for treating lysosomal disorders | |
| HK1217492A1 (zh) | 作爲刺猬信号通路抑制剂的杂环化合物 | |
| TW200736229A (en) | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | |
| MX2009005516A (es) | Derivados de urea y de sulfamida en calidad de inhibidores de tafia. | |
| WO2007115805A3 (en) | Aurora kinase inhibitors | |
| NZ706418A (en) | Azaquinazoline carboxamide derivatives | |
| WO2011046905A3 (en) | Pharmaceutical compositions | |
| TN2010000518A1 (en) | Macrocyclic urea and sulfamide derivatives a s inhibitors of tafla | |
| TW200735880A (en) | Medicinal compositions for preventing or treating heart failure |